Neuartige Fusionsproteine für Verlängerte Halbwertszeit von Vegf-Bindenden Proteinen
Anmelder: NAVIGO PROTEINS GMBH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP4803536
- Anmeldetag
- 6. März 2025
- Veröffentlichung
- 9. September 2026
- Rechtsraum
- EP
- IPC
- C07K14/71, A61K38/16
Abstract
The present invention relates to novel fusion proteins with prolonged half-life of VEGF binding proteins. The invention refers to novel engineered fusion proteins for use in anti-angiogenic therapy, in particular for treating angiogenesis-related diseases and disorders of the eye. The fusion proteins comprise a subunit that specifically binds to serum albumin. In addition to the serum albumin binding protein, the new fusion proteins comprise a protein therapeutically effective in treating diseases of the eye, such as Aflibercept. The fusion proteins are particularly well-suited for medical applications that require extended half-life of eye specific therapeutic proteins.
Anmelder
- Firma
- NAVIGO PROTEINS GMBH
- Land
- 🇩🇪 Deutschland